CHAPTER 226 SB 91 – FINAL VERSION

01/30/14 0121s 30Apr2014... 1357h

2014 SESSION

 $\frac{13\text{-}0878}{01/05}$

SENATE BILL	91
AN ACT	relative to drug use not approved by the Food and Drug Administration.
SPONSORS:	Sen. Carson, Dist 14; Rep. Emerson, Ches 11
COMMITTEE:	Commerce

AMENDED ANALYSIS

This bill prohibits insurers from requiring use of a prescription drug for an indication not approved by the Food and Drug Administration unless certain circumstances exist.

Explanation:Matter added to current law appears in **bold italics.**Matter removed from current law appears [in brackets and struckthrough.]Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.

CHAPTER 226 SB 91 – FINAL VERSION

01/30/14 0121s 30Apr2014... 1357h

 $\frac{13\text{-}0878}{01/05}$

STATE OF NEW HAMPSHIRE

In the Year of Our Lord Two Thousand Fourteen

AN ACT relative to drug use not approved by the Food and Drug Administration.

Be it Enacted by the Senate and House of Representatives in General Court convened:

226:1 Off-Label Prescription Drugs. Amend RSA 415:6-g, I to read as follows:

I. No insurer that issues or renews any individual policy of accident or health insurance providing benefits for medical or hospital expenses and providing coverage for prescription drugs shall:

5 (a) Exclude coverage for any such drug for a particular indication on the ground that the 6 drug has not been approved by the Food and Drug Administration (FDA) for that indication, if such 7 drug is recognized for treatment of such indication in one of the standard reference compendia or in 8 the medical literature [as recommended by current American Medical Association (AMA) policies]; 9 or

10 (b) As a condition of coverage, impose use of an alternative drug not approved 11 by the FDA for the indication being treated, unless such alternative drug is recognized for 12 treatment of such indication in one of the standard reference compendia or in the medical 13 literature. An override of such condition of coverage shall be expeditiously granted 14 consistent with RSA 420-J:7-b, II whenever the prescriber can demonstrate that the 15 alternative drug:

- 16 (1) Has been ineffective in the treatment of the insured's medical condition
 17 in the past;
- 18 (2) Is expected to be ineffective based on the known relevant physical or
 19 mental characteristics of the insured and the known characteristics of the drug regimen;
- 20 (3) Will cause or will likely cause an adverse reaction or other physical
 21 harm to the insured; or

(4) Is not in the insured's best interest, based on medical necessity consistent
 with RSA 420-J:7-b, II.

226:2 Off-Label Prescription Drugs. Amend RSA 415:18-j, I to read as follows:

I. No insurer that issues or renews any policy of group accident or health insurance providing benefits for medical or hospital expenses and providing coverage for prescription drugs shall:

28

24

1

(a) Exclude coverage for any such drug for a particular indication on the ground that the

CHAPTER 226 SB 91 – FINAL VERSION - Page 2 –

1	drug has not been approved by the Food and Drug Administration (FDA) for that indication, if such
2	drug is recognized for treatment of such indication in one of the standard reference compendia or in
3	the medical literature [as recommended by current American Medical Association (AMA) policies];
4	or
5	(b) As a condition of coverage, impose use of an alternative drug not approved
6	by the FDA for the indication being treated, unless such alternative drug is recognized for
7	treatment of such indication in one of the standard reference compendia or in the medical
8	literature. An override of such condition of coverage shall be expeditiously granted
9	consistent with RSA 420-J:7-b, II whenever the prescriber can demonstrate that the
10	alternative drug:
11	(1) Has been ineffective in the treatment of the insured's medical condition
12	in the past;
13	(2) Is expected to be ineffective based on the known relevant physical or
14	mental characteristics of the insured and the known characteristics of the drug regimen;
15	(3) Will cause or will likely cause an adverse reaction or other physical
16	harm to the insured; or
17	(4) Is not in the insured's best interest, based on medical necessity consistent
18	with RSA 420-J:7-b, II.
19	226:3 Effective Date. This act shall take effect 60 days after its passage.
20	
21	Approved: July 14, 2014
22	Effective Date: September 12, 2014